Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--May 7, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY.
馬薩諸塞州沃特敦--(美國商業資訊)--2024年5月7日-- Enanta 製藥有限公司 致力於爲病毒學和免疫學適應症開發小分子藥物的臨床階段生物技術公司納斯達克股票代碼：ENTA）今天宣佈，總裁兼首席執行官傑伊·盧利博士和首席產品戰略官塔拉·基弗博士將於美國東部時間2024年5月14日上午10點在紐約州紐約參加JMP證券生命科學會議的爐邊談話。
A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
訪問Enanta網站 “投資者” 頁面上的 “活動和演講” 部分即可觀看該活動的網絡直播，網址爲 www.enanta.com。演講結束後將提供網絡直播的重播，並將存檔至少 30 天。
About Enanta Pharmaceuticals, Inc.
關於 Enanta 製藥有限公司
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.
Enanta正在利用其穩健的、以化學爲導向的方法和藥物發現能力，成爲病毒學和免疫學適應症小分子藥物發現和開發領域的領導者。Enanta的研發項目目前側重於呼吸道合胞病毒（RSV）和慢性自發性蕁麻疹（CSU），該公司此前已經開發了用於SARS-CoV-2（COVID-19）和慢性乙型肝炎病毒（HBV）感染的臨床階段化合物。
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET(U.S.) and MAVIRET(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit http://www.enanta.com for more information.
Glecaprevir是Enanta發現的一種蛋白酶抑制劑，是治療慢性丙型肝炎病毒感染（HCV）的主要治療方案之一，由艾伯維在多個國家以商品名MAVYRET出售（美國）和 MAVIRET（前美國）（格列卡普雷韋/匹布倫他韋）。Enanta從與艾伯維合作開發的HCV產品中獲得的部分特許權使用費爲Enanta的運營提供了持續的資金。請訪問 http://www.enanta.com 了解更多信息。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507114970/en/
Media and Investors Contact:
Jennifer Viera
jviera@enanta.com
媒體和投資者聯繫方式：
詹妮弗·維埃拉
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
來源：Enanta Pharmicals, Inc
譯文內容由第三人軟體翻譯。